

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Carbidopa / Levodopa Formulation

Manufacturer or supplier's details

Company : Organon & Co.
Address : Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil B-2220
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Acute toxicity (Oral) : Category 4
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Central nervous system)
Short-term (acute) aquatic hazard : Category 3
Long-term (chronic) aquatic hazard : Category 3

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :

Signal Word : Danger

Hazard Statements : H302 Harmful if swallowed.
H361d Suspected of damaging the unborn child.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H412 Harmful to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

P201 Obtain special instructions before use.
P260 Do not breathe dust.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Levodopa	59-92-7	Acute toxicity (Oral), Category 4 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure (Oral) (Central nervous system), Category 1 Short-term (acute) aquatic hazard, Category 3 Long-term (chronic) aquatic hazard, Category 3	>= 70 -< 90
Carbidopa	38821-49-7	Acute toxicity (Oral), Category 4 Short-term (acute) aquatic hazard, Category 3 Long-term (chronic) aquatic hazard, Category 3	>= 10 -< 20
Cellulose	9004-34-6		>= 1 -< 5
Starch	9005-25-8		>= 1 -< 5
Magnesium stearate	557-04-0		>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

		advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	Harmful if swallowed. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of

Carbidopa / Levodopa Formulation

Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

- engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers. Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Levodopa	59-92-7	TWA	500 µg/m ³ (OEB 2)	Internal
Carbidopa	38821-49-7	TWA	2,000 µg/m ³ (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection : Chemical-resistant gloves
- Material
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

Skin and body protection : aerosols.
: Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, dynamic : No data available

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1.952 mg/kg
Method: Calculation method

Components:

Levodopa:

Acute oral toxicity : LD50 (Rat): 1.780 mg/kg
LD50 (Mouse): 2.363 mg/kg

Carbidopa:

Acute oral toxicity : LD50 (Rat): 4.810 mg/kg
LD50 (Mouse): 1.750 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Carbidopa / Levodopa Formulation

Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Carbidopa:**

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Carbidopa:**

Species : Rabbit
Result : Mild eye irritation

Starch:

Species : Rabbit
Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

Result : No eye irritation
 Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Levodopa:**

Species : Guinea pig
 Result : Not a skin sensitizer.

Carbidopa:

Remarks : No data available

Starch:

Test Type : Maximization Test
 Routes of exposure : Skin contact
 Species : Guinea pig
 Result : negative

Magnesium stearate:

Test Type : Maximization Test
 Routes of exposure : Skin contact
 Species : Guinea pig
 Method : OECD Test Guideline 406
 Result : negative
 Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Levodopa:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: Chromosomal aberration
 Test system: mouse lymphoma cells
 Result: equivocal

Test Type: Micronucleus test
 Test system: Chinese hamster lung cells
 Result: positive

Test Type: sister chromatid exchange assay
 Test system: Chinese hamster lung cells

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

Result: positive

Carbidopa:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Levodopa:**

Species : Rat

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Carbidopa:

Species : Rat
 Application Route : Oral
 Exposure time : 96 weeks
 : 135 mg/kg body weight
 Result : negative

Cellulose:

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Levodopa:**

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 100 mg/kg body weight
 Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: LOAEL: 125 mg/kg body weight
 Symptoms: Skeletal malformations., Visceral malformations.
 Result: positive

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 10 mg/kg body weight

Test Type: Development
 Species: Mouse
 Application Route: Oral
 Developmental Toxicity: LOAEL: 500 mg/kg body weight
 Symptoms: Effects on fetal development.
 Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Carbidopa:

Carbidopa / Levodopa Formulation

Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 120 mg/kg body weight
Symptoms: Reduced body weight
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 120 mg/kg body weight
Result: No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 120 mg/kg body weight
Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Carbidopa / Levodopa Formulation

Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
 Date of first issue: 23.01.2015

Components:**Levodopa:**

Routes of exposure : Oral
 Target Organs : Central nervous system
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Levodopa:**

Species : Rat
 LOAEL : 100 mg/kg
 Application Route : Oral
 Exposure time : 106 Weeks
 Target Organs : Central nervous system
 Symptoms : Salivation

Species : Monkey
 LOAEL : 100 mg/kg
 Application Route : Oral
 Exposure time : 22 Weeks
 Target Organs : Central nervous system

Carbidopa:

Species : Rat
 LOAEL : 25 mg/kg
 Application Route : Oral
 Exposure time : 96 Weeks
 Remarks : No significant adverse effects were reported

Species : Monkey
 NOAEL : 135 mg/kg
 Application Route : Oral
 Exposure time : 1 y
 Remarks : No significant adverse effects were reported

Species : Dog
 NOAEL : 5 mg/kg
 LOAEL : 15 mg/kg
 Application Route : Oral
 Exposure time : 238 d
 Symptoms : Diarrhea, Vomiting, Tremors

Cellulose:

Species : Rat
 NOAEL : ≥ 9.000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Starch:

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

Species	:	Rat
NOAEL	:	>= 2.000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days
Method	:	OECD Test Guideline 410

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Levodopa:**

Ingestion	:	Symptoms: Nausea, central nervous system effects, Drowsiness
-----------	---	--------------------------------------------------------------

Carbidopa:

Ingestion	:	Symptoms: involuntary movement
-----------	---	--------------------------------

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Levodopa:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 16 mg/l Exposure time: 48 h
-----------------------------------------------------	---	-------------------------------------------------------------------

Carbidopa:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 35,3 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
-----------------------------------------------------	---	--------------------------------------------------------------------------------------------------------

Cellulose:

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	------------------------------------------------------------------------------------------------------------------------------

Magnesium stearate:

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
------------------	---	----------------------------------------------------------------------------------------------------------------------------------------------

Carbidopa / Levodopa Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
 Exposure time: 47 h
 Test substance: Water Accommodated Fraction
 Method: Directive 67/548/EEC, Annex V, C.2.
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
 Exposure time: 16 h
 Test substance: Water Accommodated Fraction
 Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable.
 Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Levodopa:**

Partition coefficient: n-octanol/water : log Pow: -2,39

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version 5.6 Revision Date: 10.10.2020 SDS Number: 50109-00016 Date of last issue: 23.03.2020
Date of first issue: 23.01.2015

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

International Regulations

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

SECTION 16. OTHER INFORMATION

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Carbidopa / Levodopa Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.6	10.10.2020	50109-00016	Date of first issue: 23.01.2015

BR / Z8